Personalis Inc Revenue Growth Rates (PSNL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Personalis Inc   (NASDAQ: PSNL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

PSNL's Revenue Growth by Quarter and Year

Personalis Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PSNL/growth
https://api.csimarket.com/api/v1/companies/PSNL/fundamentals
https://api.csimarket.com/api/v1/companies/PSNL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PSNL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 25.60
2nd Quarter June 22.36
1st Quarter March 15.47
FY 63.43

PSNLs Annual Revenue
Personalis Inc 's Revenue in the fiscal year 2025 $ 69.65 millions
Personalis Inc 's Revenue in the fiscal year 2024 $ 84.61 millions
Personalis Inc 's Revenue in the fiscal year 2023 $ 73.48 millions
Personalis Inc 's Revenue in the fiscal year 2022 $ 65.05 millions
Personalis Inc 's Revenue in the fiscal year 2021 $ 85.49 millions




PSNL Revenue third quarter 2026 Y/Y Growth Comment
Personalis Inc achieved in the third quarter 2026, above Company average Revenue rise of 76.52% year on year, to $ 25.60 millions.

Looking into third quarter 2026 results within Medical Laboratories industry 22 other companies have achieved higher Revenue growth. While Personalis Inc ' s Revenue jump of 76.52% ranks overall at the positon no. 2342 in the third quarter 2026.


PSNL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 76.52 %
2nd Quarter June 30 %
1st Quarter March -24.94 %
FY   -

Financial Statements
Personalis Inc 's third quarter 2026 Revenue $ 25.60 millions PSNL's Income Statement
Personalis Inc 's third quarter 2025 Revenue $ 14.50 millions Quarterly PSNL's Income Statement


PSNL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 14.47 %
2nd Quarter June 44.54 %
1st Quarter March -10.84 %
FY (Year on Year)   -


Back to PSNL Growth rate Comparisons >> Back to PSNL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #341
Overall #2342

Revenue Y/Y Growth Statistics
High Average Low
319.44 % 37.15 % -24.71 %
(Mar 31 2021)   (Mar 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #341
Overall #2342
Revenue Y/Y Growth Statistics
High Average Low
319.44 % 37.15 % -24.71 %
(Mar 31 2021)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Personalis Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
111.31 % 7.5 % -34.65 %
(Jun 30 2018)  


PSNL's III. Quarter Q/Q Revenue Comment
Personalis Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 14.47%, to $ 25.60 millions, from $22.36 millions in the second quarter.

Within Medical Laboratories industry only one company achieved higher sequential Revenue growth. While Personalis Inc 's Revenue growth quarter on quarter, overall rank is 277.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #72
Overall #277
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #72
Overall #277
Revenue Q/Q Growth Statistics
High Average Low
111.31 % 7.5 % -34.65 %
(Jun 30 2018)  


PSNL's III. Quarter Q/Q Revenue Comment
Personalis Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 14.47%, to $ 25.60 millions, from $22.36 millions in the second quarter.

Within Medical Laboratories industry only one company achieved higher sequential Revenue growth. While Personalis Inc 's Revenue growth quarter on quarter, overall rank is 277.


Personalis Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 69.67
Y / Y Revenue Growth (TTM) -13.26 %
Year on Year Revenue Growth Overall Ranking # 2584
Seqeuential Revenue Change (TTM) 7.99 %
Seq. Revenue Growth (TTM) Overall Ranking # 3044


Cumulative Revenue growth Comment
Personalis Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Personalis Inc 's annual Revenue improvement would be -13.26% year on year to $70 millions.

In the Healthcare sector 372 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 967 to 2584.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 373
Overall # 2584

Revenue TTM Y/Y Growth Statistics
High Average Low
72.62 %
 7.13 %
-24.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 417
S&P 500 # 3044
Cumulative Revenue growth Comment
Personalis Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Personalis Inc 's annual Revenue fall would be -13.26% year on year to $70 millions.

In the Healthcare sector 372 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 967 to 2584.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 373
Overall # 2584

Revenue TTM Y/Y Growth Statistics
High Average Low
72.62 %
7.13 %
-24.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 417
S&P 500 # 3044




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PSNL's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions


About Personalis Inc Revenue Growth Rates (PSNL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Personalis Inc (CIK 1527753).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-447201
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Personalis Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.